About: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $126.39 (-0.15%)
PVLA NASDAQ Palvella Therapeutics, Inc
Palvella Therapeutics, Inc share price
PVLA price activity
Last Price
$126.390
Change (24hr)
-0.19 USD (0.15%)
Volume
102.08K
Volume (4w avg)
-
Open
$125.09
Day Range
$123.48 - $127.91
Previous Close
$126.58
Last Trade
22 Oct, 8:00 pm GMT+0
Delayed
22 Oct, 8:00 pm GMT+0
PVLA price performance
Delayed
22 Oct, 8:00 pm GMT+0
PVLA Market Signals